A Study to Compare Insulin Pump With Conventional Treatment in Type 2 Diabetes

A Study to Compare the Efficacy and Safety of Insulin Pump Treatment in Patients With Uncontrolled Type 2 Diabetes Mellitus

Insulin deficiency resulted from progressive beta cell failure and insulin resistance in type 2 diabetes requires exogenous insulin therapy, escaping from oral antihyperglycemic agents. Previous data have been suggested that continuous subcutaneous insulin infusion (CSII) does not only have efficacy in glucose control but also restore beta cell failure.

The investigators plan to compare the efficacy/safety and beta cell function between insulin pump treatment and the intensification of conventional treatment in patients with uncontrolled type 2 diabetes.

Inclusion Criteria:

• Type 2 diabetes
• age: 18 ~ 85 yrs
• HbA1c: > 7.5%
• no change of anti-diabetic medication within 3 months

Exclusion Criteria:

• systemic corticosteroid administered within previous 6 months
• pregnancy
• severe liver or renal disease, heart failure
• History of cancer within 5 years
• Thyroid disease
• Anti-obesity drugs or slimming products within previous 3 months